All Clinical Trials in Canada

A listing of 3904 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

Canada

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Post-Operative Urinary Retention on Revision Knee Arthroplasty: the Role of Intrathecal Morphine

NCT07050277

Recruiting

Revision total knee arthroplasty (rTKA) is a frequently performed procedure. Adequate pain management is an important feature, especially for fast-track and Enhanced Recovery After Surgery (ERAS) programs. The multimodal approach, including single shot or continuous nerve blocks with catheters and spinal or epidural morphine, is a stablished strategy. Although the administration of intrathecal morphine (IM) has been shown to significantly reduce pain scores, it is not free of adverse effects. Po... Read More

Gender:

ALL

Ages:

21 years and above

Trial Updated:

06/25/2025

Locations: Mount Sinai Hospital, Toronto, Ontario

Conditions: Arthroplasties, Knee Replacement, Nerve Block, Urinary Retention Postoperative, Anesthesia, Spinal

Learn More ›

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

NCT06689956

Recruiting

This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.

Gender:

ALL

Ages:

All

Trial Updated:

06/25/2025

Locations: Mayo Clinic in Rochester, Rochester, Minnesota +19 locations

Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023

Learn More ›

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)

NCT04855396

Recruiting

There are no therapeutic agents that have been shown to improve outcomes from severe traumatic brain injury (TBI). Critical barriers to progress in developing treatments for severe TBI are the lack of: 1) monitoring biomarkers for assessing individual patient response to treatment; 2) predictive biomarkers for identifying patients likely to benefit from a promising intervention. Currently, clinical examination remains the fundamental tool for monitoring severe TBI patients and for subject selection in clinical trials. However, these patients are typically intubated and sedated, limiting the utility of clinical examinations. Validated monitoring and predictive biomarkers will allow titration of the dose of promising therapeutics to individual subject response, as well as make clinical trials more efficient by enabling the enrollment of subjects likely to benefit. Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL) and high sensitivity c-reactive protein (hsCRP) are promising biomarkers that may be useful as 1) monitoring biomarkers; 2) predictive biomarkers in severe TBI trials. Although the biological rationale supporting their use is strong, significant knowledge gaps remain. To address these gaps in knowledge, we propose an ancillary observational study leveraging an ongoing severe TBI clinical trial that is not funded to collect biospecimen. The Hyperbaric Oxygen in Brain Injury Treatment (HOBIT) trial, a phase II randomized control clinical trial that seeks to determine the dose of hyperbaric oxygen therapy (HBOT) that that has the highest likelihood of demonstrating efficacy in a phase III trial. The proposed study will: 1) validate the accuracy of candidate monitoring biomarkers for predicting clinical outcome; 2) determine the treatment effect of different doses of HBOT on candidate monitoring biomarkers; and 3) determine whether there is a biomarker defined subset of severe TBI that responds favorably to HBOT. This proposal will: 1) inform a go/no-go decision for a phase III trial of HBOT by providing adjunctive evidence of the effect of HBOT on key biological pathways through which HBOT is hypothesized to affect outcome; 2) provide evidence to support further study of the first monitoring biomarkers of severe TBI; 3) increase the likelihood of success of a phase III trial by identifying the sub-population of severe TBI likely to benefit from HBOT; 4) create a repository of TBI biospecimen which may be accessed by other investigators. This study is related to NCT04565119 Read Less

Gender:

ALL

Ages:

Between 16 years and 65 years

Trial Updated:

06/25/2025

Locations: UCSD Medical Center - Hillcrest Hospital, San Diego, California +10 locations

Conditions: Traumatic Brain Injury

Learn More ›

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

NCT05027906

Recruiting

This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

06/25/2025

Locations: University of Cincinnati, Cincinnati, Ohio +8 locations

Conditions: Prevention of Rejection in Kidney Transplant

Learn More ›

Distal Radius Interventions for Fracture Treatment

NCT05131685

Recruiting

This protocol describes a multicenter, prospective randomized superiority trial comparing functional outcomes between children treated with sedated reduction versus no formal reduction.

Gender:

ALL

Ages:

Between 4 years and 10 years

Trial Updated:

06/25/2025

Locations: Phoenix Children's Hospital, Phoenix, Arizona +25 locations

Phoenix Children's Hospital, Phoenix, Arizona

Children's Hospital of Los Angeles, Los Angeles, California

University of California- Los Angeles Medical Center, Los Angeles, California

Nemours Children's Hospital, Wilmington, Delaware

Niklaus Children's Hospital, Miami, Florida

Riley Children's Hospital, Indianapolis, Indiana

Riley Children's, Indianapolis, Indiana

Johns Hopkins Hospital, Baltimore, Maryland

Boston Children's Hospital, Boston, Massachusetts

TRIA Health Partners, Minneapolis, Minnesota

Gillette Children's Specialty Healthcare, St. Paul, Minnesota

University of Mississippi Medical Center, Jackson, Mississippi

University Hospital- Rutgers, New Brunswick, New Jersey

University of New Mexico - Carrie Tingley, Albuquerque, New Mexico

Montefiore Medical Center, Bronx, New York

New York University-Langone Health, New York, New York

Hospital of Special Surgery, New York, New York

University of Rochester Medical Center, Rochester, New York

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Cincinnati's Children's Hospital, Cincinnati, Ohio

University Hospitals Rainbow Babies & Children, Cleveland, Ohio

Oregon Health and Science University, Portland, Oregon

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Texas Scottish Rite Hospital for Children, Dallas, Texas

Texas Children's Hospital, Houston, Texas

The Hospital for Sick Children, Toronto, Not set

Conditions: Fracture Distal Radius

Learn More ›

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

NCT05549258

Recruiting

A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin \[Ig\]G).

Gender:

ALL

Ages:

Between 2 years and 17 years

Trial Updated:

06/25/2025

Locations: UCSD Altman Clinical and Translational Research Institute Building, La Jolla, California +17 locations

Conditions: Neuromyelitis Optica Spectrum Disorder

Learn More ›

Type 1 Diabetes, Exercise and Mentoring Trial

NCT06296992

Recruiting

The proposed study aims to improve the psychosocial health of adolescents living with type 1 diabetes (T1D). The study will generate knowledge and support knowledge mobilization about the effectiveness of a novel model of care for psychosocial health and self-management for adolescents living with type 1 diabetes (T1D). The novel model of care is the recruitment and training if young adult mentors to deliver a behavioural intervention that empowers adolescents with T1D to increase daily physical... Read More

Gender:

ALL

Ages:

Between 13 years and 17 years

Trial Updated:

06/25/2025

Locations: the Children's Hospital Research Institute of Manitoba and the University of Manitoba, Winnipeg, Manitoba +1 locations

Conditions: Type 1 Diabetes, Physical Activity

Learn More ›

Low Concentration Local Anesthesia Fascia Iliaca Block for Total Hip Arthroplasty

NCT06102811

Recruiting

Fascia iliaca compartment block (FICB) is a documented option for postoperative analgesia for total hip arthroplasty (THA) surgery. FICB is demonstrated to be effective in terms of analgesia and opioid requirements decrease, however it causes quadriceps motor weakness. Current available motor sparing techniques are not as effective as FICB for analgesia. Low concentration local anesthetics (LCLA) are used with excellent results for pain control with no or minimum motor block effect, in other sce... Read More

Gender:

ALL

Ages:

21 years and above

Trial Updated:

06/25/2025

Locations: Mount Sinai Hospital, Toronto, Ontario

Conditions: Arthroplasty, Replacement, Hip

Learn More ›

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103

Recruiting

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

06/25/2025

Locations: City of Hope, Duarte, California +63 locations

City of Hope, Duarte, California

UC San Diego Moores Cancer Center, La Jolla, California

University of Southern California, Los Angeles, California

Christiana Care Health System, Newark, Delaware

University of Florida Health Cancer Center, Gainesville, Florida

Sylvester Comprehensive Cancer Center, Miami, Florida

AdventHealth Cancer Institute, Orlando, Florida

H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Augusta University, Augusta, Georgia

Rush University Medical Center, Chicago, Illinois

University of Illinois Hospital & Health Sciences System, Chicago, Illinois

Advocate Aurora Health, Park Ridge, Illinois

University of Louisville, Louisville, Kentucky

University of Maryland, Baltimore, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Henry Ford Health System, Detroit, Michigan

University of Minnesota, Minneapolis, Minnesota

University of Nebraska Medical Center, Omaha, Nebraska

MD Anderson Cooper, Camden, New Jersey

Roswell Park Cancer Institute, Buffalo, New York

New York University Langone Medical Center, New York, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

University of Rochester Medical Center, Rochester, New York

University of North Carolina, Chapel Hill, North Carolina

Novant Health - Charlotte, Charlotte, North Carolina

Novant Health - Winston-Salem, Winston-Salem, North Carolina

Atrium Health Wake Forest University Health Sciences, Winston-Salem, North Carolina

Sanford Roger Maris Cancer Center, Fargo, North Dakota

University of Cincinnati Medical Center, Cincinnati, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Oklahoma, Oklahoma City, Oklahoma

Oregon Health and Science University, Portland, Oregon

Allegheny General Hospital, Natrona Heights, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Sanford Cancer Center, Sioux Falls, South Dakota

Avera Medical Group Cancer Institute, Sioux Falls, South Dakota

University of Tennessee Medical Center, Knoxville, Tennessee

Baptist Cancer Center, Memphis, Tennessee

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas

Houston Methodist, Houston, Texas

VCU Medical Center (Virginia Commonwealth University), Richmond, Virginia

Seattle Cancer Care Alliance, Seattle, Washington

St. Vincent's Hospital, Darlinghurst, New South Wales

Westmead Hospital, Westmead, New South Wales

Hollywood Private Hospital Ramsay, Nedlands, Western Australia

Princess Margaret Cancer Centre, Toronto, Ontario

Centre Hospitalier de l'Universite de Montreal (CHUM), Montréal, Not set

Universitätsklinikum Bonn, Bonn, Not set

Universitätsklinikum Carl Gustav Carus, MK I, Dresden, Not set

Universitätsklinikum Mannheim, Mannheim, Not set

Samsung Medical Center, Seoul, Gangnam-gu

Gachon Unversity Gil Medical Center, Incheon, Not set

Severance Hospital, Yonsei University, Seoul, Not set

Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Not set

National Cancer Centre Singapore, Singapore, Not set

Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Vaud

University Hospital of Zurich/ Universitätsspital Zürich, Zürich, Not set

Royal Marsden Hospital, Chelsea, England

Sarah Cannon Research Institute, London, England

University College London, London, England

The Christie NHS Foundation Trust, Manchester, England

Guy's Hospital, London, Not set

Conditions: Metastatic Non Small Cell Lung Cancer

Learn More ›

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

NCT06764771

Recruiting

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey +7 locations

Conditions: Advanced Malignant Tumors

Learn More ›

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796

Recruiting

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Gender:

ALL

Ages:

All

Trial Updated:

06/24/2025

Locations: University of Alabama Birmingham, Birmingham, Alabama +181 locations

University of Alabama Birmingham, Birmingham, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic Phoenix, Phoenix, Arizona

Arizona Cancer Center, Scottsdale, Arizona

Local Institution - 01021, Tucson, Arizona

City Of Hope, Duarte, California

University Of California San Diego Moores Cancer Center, La Jolla, California

Local Institution - 01206, Los Angeles, California

Local Institution - 01043, Sacramento, California

University of California, San Francisco- California, San Francisco, California

UCLA Medical Centre-Santa Monica, Santa Monica, California

Stanford Cancer Center, Stanford, California

University Of Colorado Cancer Center, Aurora, Colorado

Colorado Blood Cancer Institute, Denver, Colorado

Yale Cancer Center, New Haven, Connecticut

Local Institution - 01050, Washington, District of Columbia

The Mayo Clinic - Jacksonville, Davis-E, Jacksonville, Florida

Baptist Cancer Center, Miami, Florida

Local Institution - 01035, Orlando, Florida

H. Lee Moffitt Cancer Center and Research Institute University of South Florida, Tampa, Florida

Winship Cancer Institute of Emory University, Atlanta, Georgia

Northside Hospital, Inc, Atlanta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

University Of Chicago Medical Center, Chicago, Illinois

Local Institution - 01040, Maywood, Illinois

Local Institution - 01063, Niles, Illinois

IN Univ Simon Cancer Center, Indianapolis, Indiana

Local Institution - 01020, Indianapolis, Indiana

Kansas University Medical Center, Westwood, Kansas

Cancer Center of Kansas, Wichita, Kansas

University Of Kentucky, Lexington, Kentucky

Norton Cancer Institute Louisville Oncology, Louisville, Kentucky

Local Institution - 01026, New Orleans, Louisiana

University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Sidney Kimmel Comp Cancer Center at Johns Hopkins, Baltimore, Maryland

National Cancer Institute, Bethesda, Maryland

Local Institution - 01107, Boston, Massachusetts

Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts

Local Institution - 01106, Boston, Massachusetts

University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Karmanos Cancer Center Wayne State University, Detroit, Michigan

Providence Cancer Institute, Southfield, Michigan

M Health Fairview University of Minnesota Medical Center - East Bank, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

Siteman Cancer Center, Saint Louis, Missouri

University Of Nebraska Medical Center, Omaha, Nebraska

Local Institution - 01030, East Brunswick, New Jersey

Hackensack University Medical Center, Hackensack, New Jersey

Morristown Memorial Hosp, Morristown, New Jersey

Local Institution - 01053, New Brunswick, New Jersey

New York Oncology Hematology P.C., Albany, New York

Roswell Park Cancer Institute, Buffalo, New York

Local Institution - 01066, New York, New York

Weill Cornell Medicine / New York Presbyterian Hospital, New York, New York

Icahn School Of Medicine At Mount Sinai, New York, New York

Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Local Institution - 01051, Rochester, New York

Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Novant Health, Salisbury, North Carolina

Oncology Hematology Care, Inc., Cincinnati, Ohio

University Hospitals of Cleveland, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Local Institution - 01074, Columbus, Ohio

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma

Willamette Valley Cancer Institute, Eugene, Oregon

Providence Portland Medical Center, Portland, Oregon

Oregon Health and Science University OHSU, Portland, Oregon

Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia, Pennsylvania

University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

UPMC Cancer Pavillion, Pittsburgh, Pennsylvania

Hematology and Oncology Associates of SC, LLC, Greenville, South Carolina

Local Institution - 01064, Sioux Falls, South Dakota

Sarah Cannon Research Inst, Nashville, Tennessee

Texas Oncology, Dallas, Texas

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

UT Southwestern Medical Center, Dallas, Texas

University of Texas- MD Anderson, Houston, Texas

Sam Clinical Research Center, San Antonio, Texas

Local Institution - 01033, Temple, Texas

Texas Oncology, P.A. - Tyler, Tyler, Texas

University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah

Intermountain Healthcare - LDS Hospital, Salt Lake City, Utah

University Of Virginia Health System, Charlottesville, Virginia

Local Institution - 01045, Norfolk, Virginia

Local Institution - 01023, Richmond, Virginia

Swedish Cancer Institute, Seattle, Washington

Local Institution - 01060, Seattle, Washington

Fred Hutchinson Cancer Center, Seattle, Washington

Local Institution - 01055, Tacoma, Washington

University Of Wisconsin, Madison, Wisconsin

Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin

Local Institution - 01069, Wauwatosa, Wisconsin

Peter MacCallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Fiona Stanley Hospital, Murdoch, Western Australia

Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien, Wien, Not set

Jules Bordet Institut, Anderlecht, Not set

Universitair Ziekenhuis Brussel, Brussel, Not set

Local Institution - 05200, Gent, Not set

Uz Gent, Gent, Not set

University Hospital Leuven, Leuven, Not set

Local Institution - UNK 2, Leuven, Not set

University Of Calgary, Calgary, Alberta

Local Institution - 02802, Vancouver, British Columbia

Local Institution - 02801, Hamilton, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

CIUSSS de l'Est-de-l'Ile-de-Montreal, Montreal, Quebec

Helsinki University Central Hospital (HUCH), Helsinki, Not set

Hopital Henri Mondor, Creteil-Paris, Not set

CHRU de Lille France, Lille Cedex, Not set

Local Institution - 09601, Lyon, Not set

Local Institution - 09400, Marseille Cedex 9, Not set

Local Institution - 09602, Marseille Cedex 9, Not set

CHU Montpellier - Hôpital Saint Eloi, Montpellier CEDEX 5, Not set

Chu Hotel Dieu, Nantes Cedex 01, Not set

Hopital Saint Louis, Paris, Not set

Hospital Saint Louis, Paris, Not set

Local Institution - 09600, Paris, Not set

Centre Hospitalier Universitaire (CHU) de Bordeaux - Hopital Haut-Leveque, Pessac, Not set

Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, Not set

CHU La Miletrie, Poitiers Cedex, Not set

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse CEDEX 9, Not set

Gustave Roussy, Villejuif, Not set

Robert-Rossle-Klinik im HELIOS Klinikum Berlin-Buch Klinik fur Hamatologie, Onkologie u. Tumorimmuno, Berlin, Not set

Local Institution - 03155, Berlin, Not set

Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Not set

Local Institution - 03513, Dusseldorf, Not set

Local Institution - 03500, Frankfurt, Not set

Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Not set

Universitatsklinikum Heidelberg, Heidelberg, Not set

Kinikum der Universitaeat zu Koeln, Koeln, Not set

Local Institution - 03454, Muenster, Not set

LMU Klinikum der Universität, München, Not set

Local Institution - 03503, Tuebingen, Not set

University Hospital of Ulm, Ulm, Not set

Universitatsklinikum Wurzburg Medizinische Klinik und Poliklinik II, Würzburg, Not set

Ospedali Riuniti di Ancona, Ancona, Not set

Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set

Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Not set

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Naples, Not set

Local Institution - 07500, Roma, Not set

Ospedale Pediatrico Bambino Gesu, Rome, Not set

Istituto Clinico Humanitas, Rozzano (MI), Not set

Local Institution - 07610, Torino, Not set

Azienda Sanitaria Ospedaliera San Giovanni Battista Molinette, Turin, Not set

Hokkaido University Hospital, Sapporo-shi, Hokkaido

National Cancer Center Hospital, Chuo-ku, Tokyo

Toranomon Hospital, Minato-ku, Tokyo

Local Institution - 13202, Bunkyo-ku, Not set

Kyushu University Hospital, Fukuoka, Not set

Tokai University Hospital, Isehara City, Kanagawa, Not set

Nagoya City University Hospital, Nagoya, Not set

Osaka Metropolitan university Hospital, Osaka, Not set

Japan Red Cross Medical Center, Shibuya-ku, Not set

Jichi Medical University Hospital, Shimotsuke, Not set

Local Institution - 13804, Shinjuku City, Not set

Local Institution - 04650, Amsterdam, Not set

Erasmus Medical Center - Daniel den Hoed, Rotterdam, Not set

Local Institution - 04400, Utrecht, Not set

Oslo Universitetssykehus, Oslo, Not set

Institutul Clinic Fundeni, Bucuresti, Not set

Hospital Universitario Vall D hebron, Barcelona, Not set

Hospital Universitari Germans Trias i Pujol ICO Badalona, Barcelona, Not set

Institut Clinic de Nefrologia i Urologia - Hospital Clinic i Provincial de Barcelona, Barcelona, Not set

Hospital San Joan de Deu Barcelona, Esplugues de Llobregat, Not set

Hospital Infantil Universitario Nino Jesus, Madrid, Not set

Hospital 12 De Octubre, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Virgen Del Rocio, Sevilla, Not set

Karolinska University Hospital Huddinge, Stockholm, Not set

Inselspital Bern, Bern, Not set

Local Institution - 10850, Leeds, Not set

Kings College Hospital, London, Not set

UCL Cancer Institute, London, Not set

Christie Hospital Nhs Trust, Manchester Withington, Not set

Somers Cancer Research Building, Shirley Southampton, Not set

Conditions: Neoplasms

Learn More ›

Confirming the Effectiveness of Online Guided Self-Help Family-Based Treatment for Adolescent Anorexia Nervosa

NCT05563649

Recruiting

With an incidence rate of about 1%, Anorexia Nervosa (AN) is a serious mental disorder associated with high mortality, morbidity, and cost. AN in youth is more responsive to early treatment but becomes highly resistant once it has taken an enduring course. The first-line treatment for adolescents with AN is Family Based Treatment (FBT). While FBT can be delivered using videoconferencing (FBT-V), therapists' limited availability hampers scalability. Guided self-help (GSH) versions of efficacious... Read More

Gender:

ALL

Ages:

Between 12 years and 18 years

Trial Updated:

06/24/2025

Locations: Stanford University, Stanford, California +1 locations

Conditions: Anorexia Nervosa

Learn More ›